| Source: |
| Type: |
| Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin. EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin). EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis. |
| 6441- | SAO, | Sandalwood Album Oil as a Botanical Therapeutic in Dermatology |
| - | Review, | PSA, | NA |
| 4485- | Se, | Selenium stimulates the antitumour immunity: Insights to future research |
| - | Review, | NA, | NA |
| 1135- | Selenate, | Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation |
| - | in-vitro, | CRC, | DLD1 |
| 3198- | SFN, | Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells |
| - | in-vitro, | Pca, | NA |
| 1136- | SFN, | Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells |
| - | in-vitro, | Lung, | NA | - | in-vivo, | NA, | NA |
| 1014- | SFN, | Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 110- | SFN, | Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway |
| - | in-vivo, | PC, | NA |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 1466- | SFN, | Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway |
| - | vitro+vivo, | Thyroid, | FTC-133 |
| 1462- | SFN, | Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 1434- | SFN, | GEM, | Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity |
| - | in-vitro, | CCA, | HuCCT1 | - | in-vitro, | CCA, | HuH28 | - | in-vivo, | NA, | NA |
| 1730- | SFN, | Sulforaphane: An emergent anti-cancer stem cell agent |
| - | Review, | Var, | NA |
| 3301- | SIL, | Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid |
| - | Review, | Var, | NA |
| 3296- | SIL, | Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway |
| - | in-vitro, | Oral, | Ca9-22 | - | in-vivo, | Oral, | YD10B |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | NA, | NA |
| 1127- | SIL, | Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1 |
| - | in-vitro, | Lung, | A549 |
| 2359- | SK, | Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery |
| - | in-vivo, | Liver, | NA |
| 2197- | SK, | Shikonin derivatives for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2196- | SK, | Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species |
| - | Review, | Var, | NA |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Nor, | MCF12A | - | in-vivo, | NA, | NA |
| 5075- | SSE, | Sodium selenite inhibits proliferation and metastasis through ROS‐mediated NF‐κB signaling in renal cell carcinoma |
| - | vitro+vivo, | RCC, | 786-O |
| - | in-vitro, | NSCLC, | A549 |
| 6436- | T4O, | Terpinen-4-ol suppresses proliferation and motility of cutaneous squamous cell carcinoma cells by enhancing calpain-2 expression |
| - | in-vitro, | Melanoma, | A431 |
| 1138- | TQ, | Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2084- | TQ, | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
| - | Review, | Var, | NA |
| 1929- | TQ, | Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells |
| - | in-vitro, | Bladder, | 5637 | - | in-vitro, | Bladder, | T24/HTB-9 |
| 3407- | TQ, | Thymoquinone and its pharmacological perspective: A review |
| - | Review, | NA, | NA |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3423- | TQ, | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
| - | Review, | Var, | NA |
| 3571- | TQ, | The Role of Thymoquinone in Inflammatory Response in Chronic Diseases |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 5911- | TV, | Thymol Isolated from Thymus vulgaris L. Inhibits Colorectal Cancer Cell Growth and Metastasis by Suppressing the Wnt/β-Catenin Pathway |
| - | vitro+vivo, | CRC, | NA |
| 1139- | UA, | Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells |
| - | in-vitro, | Lung, | A549 |
| 4856- | Uro, | Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro |
| - | in-vitro, | NPC, | CNE1 | - | in-vitro, | NPC, | CNE2 |
| 4838- | Uro, | The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention |
| - | Review, | Var, | NA |
| 4844- | Uro, | Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 633- | VitC, | Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment |
| - | Analysis, | NA, | NA |
| 1217- | VitC, | High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition |
| - | in-vitro, | BC, | Bcap37 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 4618- | VitD3, | Vitamin D sensitizes cervical cancer to radiation-induced apoptosis by inhibiting autophagy through degradation of Ambra1 |
| - | in-vivo, | Cerv, | NA |
| 2366- | VitD3, | Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 1816- | VitK2, | Role of Vitamin K in Selected Malignant Neoplasms in Women |
| - | Review, | Var, | NA |
| - | in-vitro, | Oral, | NA | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | HaCaT |
| 1820- | VitK3, | Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | SW-620 |
| 1222- | Z, | Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition |
| - | in-vitro, | Ovarian, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:96 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid